Sign In
Buy REGN
$618.95
+16.03 (+2.66%)
At Close: Jun 03, 2026
Sanofi and Regeneron's Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria
Approval for children aged 2 to 11 years with CSU who remain symptomatic despite H1 antihistamine treatment based primarily on data from the LIBERTY-CUPID clinical trial program
Regeneron (REGN) Earnings Expected to Grow: Should You Buy?
11:01am, Wednesday, 22'nd Apr 2026
Regeneron (REGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Got $2,000? These Biotech Stocks Are Worth Considering for Long-Term Growth
04:56pm, Tuesday, 21'st Apr 2026
It will be a turbulent ride, but patient investors might come out of it much richer.
As published in The Lancet and presented at AAN, NIMBLE trial met its primary and key secondary endpoints at week 24, demonstrating potential best-in-class efficacy and convenience in gMG
Regeneron Announces Investor Conference Presentations
04:05pm, Monday, 20'th Apr 2026
TARRYTOWN, N.Y., April 20, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:
Lbp Am Sa Sells 12,873 Shares of Regeneron Pharmaceuticals, Inc. $REGN
04:05am, Saturday, 18'th Apr 2026
Lbp Am Sa decreased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 68.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commi
Regeneron Boosts Cancer Pipeline Through Telix Collaboration
02:00pm, Tuesday, 14'th Apr 2026
Regeneron teams up with Telix in a 50/50 radiopharma deal, betting on next-gen cancer therapies to expand its oncology pipeline and long-term growth.
SNY & REGN's Dupixent Gets EU Approval for Pediatric Use in Urticaria
10:46am, Monday, 13'th Apr 2026
Sanofi wins EC nod to expand Dupixent use to children aged 2 to 11 years with CSU, backed by phase III data, marking the first targeted option in the EU.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
09:56am, Monday, 13'th Apr 2026
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Telix and Regeneron Announce Strategic Radiopharma Collaboration
06:30am, Monday, 13'th Apr 2026
MELBOURNE, Australia and INDIANAPOLIS and TARRYTOWN, N.Y., April 13, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) and Regeneron Pharmaceuticals, Inc. (N
Regeneron and Telix Announce Strategic Radiopharma Collaboration
06:30am, Monday, 13'th Apr 2026
Regeneron and Telix to co-develop and co-commercialize next-generation radiopharmaceutical therapies in a 50/50 cost and profit-sharing model
Sanofi and Regeneron's Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria
Approval in CSU for children 2 to 11 years of age is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of efficacy data showing that Dupixent significantly reduce
REGN or ILMN: Which Is the Better Value Stock Right Now?
12:40pm, Thursday, 09'th Apr 2026
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Regeneron (REGN) or Illumina (ILMN). But which of these two stocks presents investors with th
